OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China

Anthony Letai: New Research Classifies More Than 6,500 BRCA2 Variants to Improve Risk Assessment

10 Must-Read Posts In GU Oncology This Week

Ophira Ginsburg: Why ASCO Africa Was a Standout Meeting for Cancer Equity

San Diego's Largest Community-Powered Cancer Research Fundraiser Returns: Curebound Cancer Challenge to Accelerate Cures

Oncology News, Insights, Stories by OncoDaily

Agenus
Gastrointestinal Oncology

Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer

Breast Cancer
Breast Oncology

NCCN Breast Cancer Version 4.2026: Metastatic Treatment Moves Further Toward Biomarker-Driven Sequencing

CancerWorld
Voices

The Future of Oncology is Ensuring the Discoveries Reach Every Patient - CancerWorld

Nara Smith Opens Up About Her Two-Year-Old Daughter’s Cancer Battle

Laura Towart : How Much Younger Can You Get in Six Months?

2026 IBRI Global Forum on Science, Philanthropy, and Investment

Rafael Fonseca Reflects on “Many and Multiple Myeloma(s)” 23 Years Later

Asem Mansour։ CAR-T Therapy Manufacturing Advances in Jordan

Promising New Approach to Treating Bladder Cancer - Parker Institute for Cancer Immunotherapy

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

Voices
Valsamo Anagnostou

Valsamo Anagnostou: Exploring plasmaCHORD Through Fresh Perspectives

Françoise Meunier: Advancing the Right to Be Forgotten for Cancer Survivors

Jennifer S. Buell: Moving Immunotherapy Before Surgery to Change the Course of High-Risk MSS Colon Cancer

'Don't Choose This Path' Campaign Strengthens Stance Against All Forms of Smoking - KHCF/KHCC

Zack Armen: Delivering the Promise of BOT+BAL

Plan Your World Cancer Congress 2026 Experience - UICC

Advancing Cancer Research Through Stable Federal Support - AACR

FDA Approvals
Subcutaneous Isatuximab Multiple Myeloma

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant RCC

FDA Approved Decnupaz, the First ADC for Adults With BPDCN

FDA Approves FoundationOne CDx as Companion Diagnostic for TEPMETKO in METex14 NSCLC

FDA approved Atezolizumab for adjuvant treatment of MDR–positive MIBC

FDA Grants Approval for Oral Decitabine/Cedazuridine With Venetoclax in Newly Diagnosed AML

FDA Greenlit New Pancreatic Cancer Drug Daraxonrasib For Expanded Access

OncoDaily 100
100 influential survivors

100 Influential Cancer Survivors on Social Media: 2026 Edition

100 Xfluencers in Prostate Cancer: Key Opinion Leaders to follow on X (Twitter) in 2025

The 100 Most Influential CEOs in Oncology in 2025 (Full List)

The 100 Most Influential People in Oncology in 2025 (Full List)

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024

Top 100 Xfluencers in Lung Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

Celebrities and Cancer

OncoCalendar

HER2 and Colorectal Cancer: What Advocates Need to Know

Global Colon Cancer Association

29 Jul
Colorectal Cancer

ESSO Advanced Course on the Treatment of Peritoneal Surface Malignancy

European Society of Surgical Oncology

15 Oct
Peritoneal Surface Malignancy

ESSO Hands-On Course on the Minimally Invasive Management of Peritoneal Surface Malignancies

European Society of Surgical Oncology

15 Sep
Peritoneal Surface Malignancies

ESO-ESSO-ESTRO-ESP Multidisciplinary Course on Oncology for Medical Students

European Society for Radiotherapy and Oncology (ESTRO)

24 Aug
Oncology

ESO Ambassador Event on Neoadjuvant and Post-Neoadjuvant Treatment in Breast Cancer

European School of Oncology (ESO) College

30 Oct
Breast Cancer

Immune-oncology
ChemRNA: A New Generation of Simplified RNA Vaccines for Cancer Immunotherapy

ChemRNA: A New Generation of Simplified RNA Vaccines for Cancer Immunotherapy

10 Must-Read Posts in Immuno-Oncology This Week

FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer

FDA Approves Subcutaneous Isatuximab for Multiple Myeloma

FDA Immunotherapy Approvals: First Half of 2026

WHO Global Cancer Report 2026: Immunotherapy Is Transforming Cancer Care, But Access Remains the Biggest Challenge

Exclusive Comments From the Authors of Pacific Analysis on Gut Microbiome

Gastrointestinal-Oncology
ESMO GI 2026 with Davide Ciardiello

Highlights of ESMO GI 2026 in Colorectal Cancer with Davide Ciardiello

Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer

Disitamab Vedotin, Tislelizumab, and S-1 Deliver High Response Rates in HER2-Overexpressing Advanced Gastric/GEJ Cancer

WHO Global Cancer Report 2026: GI Cancers Show the Cost of Delayed Prevention, Diagnosis, and Access

Pancreatic Cancer: Early SBRT Shows Promise Before Chemoimmunotherapy

PICC-2: Toripalimab Plus Celecoxib Improves pCR in dMMR Locally Advanced Colorectal Cancer

Top 10 Pancreatic Cancer Updates – June 2026

Breast-Oncology
Germline

Germline Multigene Testing May Identify Higher-Risk Invasive Lobular Breast Cancer

Breast Cancer Incidence Is Rising Rapidly Among Asian American, Native Hawaiian, and Pacific Islander Women

NCCN Breast Cancer Version 4.2026: Metastatic Treatment Moves Further Toward Biomarker-Driven Sequencing

IM-MS Irradiation Reduced Breast Cancer Mortality but Did Not Improve Overall Survival in Node-Negative Breast Cancer

WHO Global Cancer Report 2026: Breast Cancer Survival Still Depends Too Much on Where a Woman Lives

Ovarian Stimulation With Letrozole Shows No Short-Term Molecular Impact on Breast Tumors 2026

Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer

Lung-Oncology
Risvutatug Rezetecan

Risvutatug Rezetecan Meets Overall Survival Endpoint in Phase III SCLC Trial in China

Comprehensive Genomic Profiling Delays in Lung Cancer: Biopsy-to-Order Time Remains the Biggest Barrier

Pretreatment SUVmax May Help Identify Which Early-Stage NSCLC Patients Benefit From Consecutive Daily SBRT

Can AI-Supported Navigation Help Close the Lung Nodule Follow-Up Gap?

WHO Global Cancer Report 2026: Lung Cancer Shows Why Prevention Still Saves the Most Lives

PD-L1 High Advanced NSCLC: Is Immunotherapy Alone Always Enough?

Severe Neurotoxicity After Tarlatamab in SCLC Brain Metastases: Could It Be TIAN Rather Than ICANS?

Oncology Tech
Chris Boshoff

Chris Boshoff: FDA Approves First Platinum-Free Perioperative Regimen for Muscle-Invasive Bladder Cancer

FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision

Novartis' $1.5B Myricx deal is a preclinical bet on a brand-new ADC payload

Claude Science: What Anthropic's New Research Workbench Actually Does for Oncology

Is the First AI-Designed Cancer Drug About to Be Approved?

AI Meets the Brain: Inside Insilico and SK Biopharmaceuticals’ $2.5 Billion Neuroimmune Bet

Inside DeepHealth: How RadNet's AI Bet Is Reshaping the Business of Radiology

Hematology
Epcoritamab R2

Europe Opens the Door to Epcoritamab-R² in Early Relapsed Follicular Lymphoma: A Candidate for a New 2L Standard?

FDA Approved Subcutaneous Isatuximab: Advancing Anti-CD38 Therapy Delivery in Multiple Myeloma

What the WHO Global Status Report on Cancer 2026 Means for Hematology

Outpatient Cilta-cel for Multiple Myeloma: Initial Experience in Carefully Selected Patients

Marginal Zone Lymphoma (MZL): Chronic Immune Stimulation, Heterogeneity and Beyond

Phase 3 TRIANGLE: Reassessing the Role of ASCT in Frontline Ibrutinib-Containing Therapy for MCL

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Radiotherapy
NSCLC

Unresectable Stage III NSCLC: Precision Redefines Care

A Looming Collapse: Radiation Oncology’s Access Crisis Is No Longer Theoretical 2026

OLIGOPELVIS 2 Shows Acceptable Toxicity With Salvage Nodal Radiotherapy

Early SBRT Before Chemoimmunotherapy Shows Promise in Borderline Resectable and Locally Advanced Pancreatic Cancer

HYPORT Adjuvant Trial Evaluates Quality of Life After Nodal Radiotherapy

Can SABR Replace Surgery in Selected Low-Risk Breast Cancer?

ESTRO Sets Practical Guidance for Focal Boosting in Prostate Cancer Radiotherapy 2026

OncoDaily TV
Daraxonrasib for Pancreatic Cancer: What’s Next?

Daraxonrasib for Pancreatic Cancer: What’s Next?

1000 doctors standing asco alan sandler

Why 1000 Doctors Gave This Cancer Drug A Standing Ovation?

Empowering Oncologists: Are Digital Literacy Tools Critically Important?

Empowering Oncologists: Are Digital Literacy Tools Critically Important?

ASCO

OncoDaily Highlights from ASCO 2026 Chicago, USA

Episode 17: Global Health Dialogues with Princess Dina and Eman Shannan

Episode 17: Global Health Dialogues with Princess Dina and Eman Shannan

Where You Live Shouldn't Dictate Your Cancer Survival: Dr. Benjamin Anderson

Where You Live Shouldn’t Dictate Your Cancer Survival: Dr. Benjamin Anderson

Investing in Cancer Care: Better Health, Stronger Economies: Herb Riband

Investing in Cancer Care: Better Health, Stronger Economies: Herb Riband

Kefah Mokbel

Kefah Mokbel: Can Diet Influence Cancer Risk and Outcomes?

Empowering Oncologists: How to make the most of your fellowship?

Empowering Oncologists: How to make the most of your fellowship?

STAMP Inhibitors Against CML: Prof. Timothy Hughes

STAMP Inhibitors Against CML: Prof. Timothy Hughes

Oncology's Greatest Threat: A System in Crisis

Oncology’s Greatest Threat: A System in Crisis

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition: Highlights of the event

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition: Highlights of the event

Not To Miss
IBRI

2026 IBRI Global Forum on Science, Philanthropy, and Investment

15 Posts Not To Miss From Best of ASCO Africa 2026

Top Growing Medical Universities in Africa: 2026 Edition by BIGR

WHO Calls for Urgent Action as New Cancer Cases Are Projected to Nearly Double by 2050

20 Posts Not To Miss From ESMO GI 2026, Part 2

20 Posts Not To Miss From ESMO GI 2026, Part 1

Top Growing Medical Universities in Asia: 2026 Edition by BIGR

OncoGrants
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA

ACOG Foundation 2026 Request for Grant Proposals

ACOG Foundation 2026 Request for Grant Proposals

Clinical Trial Award — DoD OCRP

Clinical Trial Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Ovarian Cancer Academy – Early-Career Investigator Award — DoD OCRP

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Investigator-Initiated Research Award — DoD Ovarian Cancer Research Program

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Kids Beating Cancer — John Voight Memorial Leukemia Research Grant

Oncologist near me
Oncologist Near Me

Oncologist Near Me – Gregory Kalemkerian: Advancing Lung Cancer Care, Research, and Education
Oncologist Near Me

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership
Oncologist Near Me

Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
Oncologist Near Me

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care
Oncologist Near Me

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine
Oncologist Near Me

Oncologist Near Me – Yelena Janjigian: A Global Leader in Gastrointestinal Oncology
Oncologist Near Me

Oncologist Near Me – Bishal Gyawali: Challenging the Status Quo in Global Oncology
Oncologist Near Me

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology
Oncologist Near Me

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research
Oncologist Near Me

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Cancer types
MCL Mantle cell lymphoma, BTK inhibitors

Mantle Cell Lymphoma (MCL): Revealing the Biology Beneath the Mantle and Modern Therapeutic Frontiers

Burkitt Lymphoma: Among the Fastest Growing Yet Most Curable Human Cancers

Diffuse Large B-Cell Lymphoma (DLBCL): Molecular Heterogeneity and Progress in Therapy

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Current Perspectives on an Ultra-Rare Malignancy

Richter Transformation (RT): When Chronic Lymphocytic Leukemia Turns Aggressive

Acute Myeloid Leukemia (AML) in 2026: The Current Landscape and Future Perspectives

Follicular Lymphoma (FL): Evolving Biology and Modern Therapeutic Paradigms

CancerWorld

Oncologists
Fatjona Kraja

Fatjona Kraja

Oncologists Location Tirana, Albania
Shubha De Sarkar

Shubha De Sarkar

Oncologists Location Jaipur, India
mahmoud hammad

Mahmoud Hammad

Oncologists Location Cairo, Egypt
Mariam Abuladze

Mariam Abuladze

Oncologists Location Tbilisi, Georgia
Alice Bernard-Tessier

Alice Bernard-Tessier

Oncologists Location Villejuif, France
Petros Grivas

Petros Grivas

Oncologists Location Seattle, USA
Jalid Sehouli

Jalid Sehouli

Oncologists Location Berlin, Germany
Ana Filipa Martins Ferreira Varges Gomes

Ana Filipa Martins Ferreira Varges Gomes

Oncologists Location Portimão, Portugal

Oncology Drugs
Sacituzumab Tirumotecan

Sacituzumab Tirumotecan: What Patients Should Know About This Emerging Cancer Treatment

Sacituzumab Tirumotecan: Clinical Development, Mechanism, and Emerging Role in Modern Oncology

Lurbinectedin: What Patients Should Know

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

Bemarituzumab: What Patients with Gastric Cancer Should Know

Bemarituzumab: Uses in Cancer, Side Effects, Dosages, Expectations and More

GSK5764227 (HS-20093): A Novel B7-H3 Targeted Antibody–Drug Conjugate Under Clinical Investigation

OncoDaily Magazine

New Paper Alert
Rodrigo Lastra del Prado

Rodrigo Lastra del Prado: Benefits of Empathetic Oncologist Patient Communication

ICRA trial

The ICRA trial: Paclitaxel Plus Tremelimumab Shows Activity After Platinum and PD-(L)1 Therapy in Metastatic Urothelial Cancer

Screening - OncoDaily

A Unified Framework for Pre-Screening and Screening Tools in Oncology Clinical Trials 2026

Cardiovascular Disease

Prevention And Management Of Cardiovascular Disease In Adults With Cancer: IC-OS And MASCC Clinical Practice Statement

EORTC–ESTRO

Endpoints in Metastases Directed Therapy for Oligometastatic Cancer A Review and Consensus by the EORTC–ESTRO OligoCare Consortium

MONTBLANC Trial

MONTBLANC Trial Recruitment Completed: Triple Immunotherapy in Advanced HCC

OncoDaily Medical Journal

Lung Cancer

10.69690/ODMJ-001-0626-7958

Evaluation of Intra-Fractional Target Position Variation during Deep Inspiration Breath-Hold (DIBH) Sessions in Lung Stereotactic Body Radiotherapy (SBRT)
Original Research

Hematology

10.69690/ODMJ-001-0526-7344

Analysis of Mortality Factors in the Pediatric Hemato-Oncology Department of the Children's Hospital of Rabat, 2022-2023
Original Research

Radiation Oncology

10.69690/ODMJ-011-0526-7409

An Independent Read-Only Verification and Risk-Management System to Maintain Radiotherapy Safety During Oncology Information System Failure
Case Reports & Case Series

Cancer Care

10.69690/ODMJ-001-0426-7451

Distinct differences in the tumour-resident microbiome between early- and late-onset colorectal cancer
Original Research

Hematology

10.69690/odmj-012-0426-7512

Frailty, infections, and bispecific antibodies in multiple myeloma: redefining supportive care in the era of T-cell redirection
Commentaries

Oncology Nursing

10.69690/ODMJ-002-0426-7359

Barriers and Facilitators of Oral Nutritional Supplement Adherence in Cancer: A Systematic Review
Reviews

Hematology

10.69690/ODMJ-011-0426-7452

Double Dilemma: Managing a Sequential Lymphoma (Case Report)
Case Reports & Case Series

Hematology

10.69690/ODMJ-011-0426-7442

Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Patients with Severe Aplastic Anemia and Multi-Drug Resistant Bacterial Infections - A Case Series
Case Reports & Case Series